The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-Negative Myeloproliferative Neoplasms

American Journal of Clinical Pathology

Volumn 144, Issue 1, 2015, Pages 165-171

  Lin, Yani ^a   Liu, Enbin ^a   Sun, Qi ^a   Ma, Jiao ^a   Li, Qinghua ^a   Cao, Zeng ^a   Wang, Jun ^a   Jia, Yujiao ^a   Zhang, Hongju ^a   Song, Zhen ^b   Ai, Xiaofei ^a   Shi, Lihui ^a   Feng, Xiaofang ^a   Li, Chenwei ^d   Wang, Jianxiang ^a,c   Ru, Kun ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b Department of Medical Service ^*  (China)

^c State Key Laboratory of Experimental Hematology   (China)

^d Sunstem Biotechnology Co Ltd   (China)

Author keywords

CALR; Diagnosis; JAK2; MPL; MPN

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; CALRETICULIN; JANUS KINASE 2; MPL PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG; CALRETICULIN, HUMAN; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR;

ADULT; AGED; CANCER DIAGNOSIS; CHINESE; CONFERENCE PAPER; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; SOMATIC MUTATION; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; GENETICS; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CALRETICULIN; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PREVALENCE; RECEPTORS, THROMBOPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84939422417     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPALP51XDIXDDV     Document Type: Conference Paper

References (35)

1. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-951.
2. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59:171-191.
3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
4. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355:2452-2466.
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycyth emia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
7. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
8. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.
9. Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21:1960-1963.
10. Scott LM, Beer PA, Bench AJ, et al. Prevalence of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol. 2007;139:511-512.
11. Jones AV, Cross NC, White HE, et al. Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. Haematologica. 2008;93:1560-1564.
12. Pikman Y,Lee BH,Mercher T,et al MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia PLoS Med. 2006; 3: e270.
13. Rumi E, Pietra D, Guglielmelli P, et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013;121:4388-4395.
14. Beer PA, Campb ell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112:141-149.
15. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472-3476.
16. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391-2405.
17. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379-2390.
18. Wang WA, Groenendyk J, Michalak M. Calreticulin signaling in health and disease. Int J Biochem Cell Biol. 2012;44:842-846.
19. Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123:1552-1555.
20. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28:1472-1477.
21. Levine RL , Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673-683.
22. Xia J, Lu MZ, Jiang YQ, et al. JAK2 V617F, MPL W515L and JAK2 exon 12 mutations in Chinese patients with primary myelofibrosis. Chin J Cancer Res. 2012;24:72-76.
23. Zhang SJ, Qiu HX, Li JY, et al. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay. Int J Lab Hematol. 2010;32:381-386.
24. Wojtaszewska M, Iwola M, Lewandowski K. Frequency and molecular charact eristics of calreticulin gene (CALR) mutations in patients with JAK2-negative myeloproliferative neoplasms. Acta Haematol. 2014;133:193-198.
25. Chen CC, Gau JP, Chou HJ, et al. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol. 2014;93:2029-2036.
26. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507-25 13.
27. Wu Z, Zhang X, Xu X, et al. The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol. 2014;7:48.
28. Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124:1062-1069.
29. Tefferi A, Wa ssie EA, Guglielmelli P, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014;89:E121-E124.
30. Pietra D, Brisci A, Rumi E, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica. 2011;96:607-611.
31. Williams DM, Kim AH, Rogers O, et al. Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol. 2007;35:1641-1646.
32. Bernardi M, Ruggeri M, Albier o E, et al. Isolated erythrocytosis in V617F negative patients with JAK2 exon 12 mutations: report of a new mutation. Am J Hematol. 2009;84:258-260.
33. Fu R,Xuan M,Zhou Y,et al Anal ysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment Leukemia. 2014; 28: 1912-1914.
34. Lundberg P, Karow A, Nienho ld R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220-2228.
35. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515WL/K mutation in essential thrombocythemia. Blood. 2008;112:844-847.